Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 monotherapy for advanced hepatocellular carcinoma after prior systemic therapy
ChiCTR2500097658Phase 2Not yet recruiting
- Sponsor
- Taixing People's Hospital
- Start
- Feb 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab, tuvonralimab and QL1706 in hepatocellular carcinoma (HCC), sponsored by Taixing People's Hospital. Primary endpoint: Objective response rate. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimabQL1706
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500097658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097658.